Results 81 to 90 of about 35,394 (206)
PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context‐Dependent Therapeutic Vulnerability
Genes, Chromosomes and Cancer, Volume 65, Issue 7, July 2026.ABSTRACT PKMYT1 has emerged as a promising therapeutic target distinguished by its tumor‐selective expression and essential role in replication stress management. Unlike WEE1, PKMYT1 is dispensable in normal cell cycles but critical for cancer cells coping with DNA damage, establishing a broad therapeutic window.
Lingxi Li +5 more
wiley +1 more source
Uterine sarcoma: a clinical case and a literature review
Acta Medica Lituanica, 2019 Background. Uterine sarcomas are rare gynaecologic tumours representing 3–7% of all uterine malignancies. The aetiology of sarcomas is still unclear: it is thought, that chromosomal translocations have influence on wide histological variety of sarcomas ...
Diana Bužinskienė +3 more
doaj +1 more source
Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape
The FEBS Journal, Volume 293, Issue 13, Page 3991-4013, July 2026.The EMILIN/Multimerin family members regulate key hallmarks of cancer—including apoptosis, angiogenesis, metastasis, and tumor microenvironment remodeling. As indicated, their function in immune evasion, drug resistance, and metabolic reprogramming remains largely unexplored.
Evelina Poletto +9 more
wiley +1 more source
Clinical Case Reports, 2018 Key Clinical Message Peritoneal sarcomatosis from uterine sarcoma is a rare disease with no effective treatment and poor prognosis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has successful results in peritoneal ...
Armando Sardi +3 more
doaj +1 more source
The FEBS Journal, Volume 293, Issue 13, Page 3954-3972, July 2026.Basement membrane (BM) homeostasis relies on a balance between integrity, controlled remodelling and pathological degradation. Increased protease expression beneath the BM, along with reduced levels of endogenous protease inhibitors, drives the transition from a continuous, protective barrier to a discontinuous interface.
Clara Legendre +2 more
wiley +1 more source
Non-puerperal uterine inversion due to uterine sarcoma
, 2006 Background: Uterine inversion is a very rare pathological condition that usually occurs in puerperium. Non-puerperal uterine inversion is exceptional and to our knowledge only a few cases of uterine inversion due to a uterine sarcoma have been reported ...
SELVAGGI L. +4 more
core +1 more source
Brachytherapy for uterine cervix-limited acute myeloid leukemia relapse
, 2022 Acute myeloid leukemia (AML) may extend to extra-medullary sites at diagnosis or at relapse, either isolated or associated with bone marrow disease. Granulocytic sarcoma of uterine cervix is rare, and there is no established treatment for this disease ...
Guillaume Beziat +7 more
core +1 more source
, 2012 Uterine leiomyosarcoma (ULMS) develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine ULMS
Nobuo Yaegashi +5 more
core
Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease [PDF]
, 2017 BACKGROUND: The aims of this study were to evaluate the impact of initial uterus-preserving surgery, such as myomectomy or subtotal hysterectomy, on the recurrence rates of patients with uterine sarcoma found incidentally and to investigate the role of ...
김성훈 +5 more
core +1 more source
Diagnostic Pathology, 2019 Background Uterine leiomyomas, in contrast to sarcomas, tend to cease growth following menopause. In the setting of a rapidly enlarging uterine mass in a postmenopausal patient, clinical distinction of uterine leiomyoma from sarcoma is difficult and ...
Alessandra J. Ainsworth +9 more
doaj +1 more source